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As demonstrated in multiple historical analyses, there are two main causes of clinical attrition; firstly 
drugs are not efficacious, and secondly they cause unacceptable toxicity, both of which can be the 
result of poor pre-clinical target validation. Target validation, one of the early stages of a drug 
discovery program, is the process of (in)validating a drug target to ensure it is significant to the 
intended disease, and unlikely to drive undesired toxicity. Target validation is vital in preventing late 
stage failures in the clinic and, if done effectively, can save pharmaceutical companies a great deal of 
time and money. As such, target validation is treated extremely seriously, as demonstrated by the 
formation of public-private partnerships, such as Open Targets, aimed to provide evidence of 
biological validity and the possible likelihood of pharmacological intervention. Central to the variety 
of molecular tools available for use in target validation are high quality small molecules called chemical 
probes. 
 A chemical probe is a tool molecule that selectively binds to a target protein, used to answer questions 
about the targets biological function and potential role in disease[1]. The strength in target validation 
is directly related to the quality of the chemical probe used. Consequently the misuse of chemical 
probes, the use of under characterized probes, and the sheer lack of high quality chemical probes 
(compared to the number of potential biological targets) can lead to inappropriate conclusions, for 
example the use of curcumin as a tool for target validation, highlighted recently by Nelson et al.[2]. 
Unfortunately, curcumin is just one of many small molecules compromising attempts at target 
validation today. Recently however, the area of chemical probes has evolved dramatically, with 
experts from medicinal chemistry, pharmacology, biology, industry and academia coming together to 
address these issues, and help learn from past mistakes. In particular, work carried out by Bunnage et 
al. has been instrumental in defining a new set of requirements. By adapting the three pillars of 
survival, Bunnage and coworkers created the following four guidelines for chemical probes: 1) The 
probe must be able to reach the site of action at pharmacologically relevant concentrations; 2) display 
in vitro evidence of target engagement and selectivity; 3) provide sufficient data to assign phenotypic 
results to an original structure or a well characterized derivative; and 4) provide cellular activity data 
to answer a hypothesis on the role of the target[3]. 
In addition to these guidelines, it has become evidently important for chemical probes to be 
accompanied by a structurally similar negative control. In the often paraphrased words of R. B. 
Woodward  ?ƚŚĞ ŽŶůǇ ŵŽĚĞů ƐǇƐƚĞŵ ǁŽƌƚŚ ƵƐŝŶŐ ŝƐ ƚŚĞ ĞŶĂŶƚŝŽŵĞƌ ? ĂŶĚ ĐŚĞŵŝĐĂů ƉƌŽďĞƐ ĂƌĞ no 
exception to this, although it should be noted that enantiomeric controls are not always possible. A 
final consideration when designing chemical probes is the importance of structural diversity. With a 
selection of different chemotypes comes a greater confidence in the experimental outcome, a reduced 
probability of finding common off targets, greater conviction that observed phenotypes are due to 
target engagement, and compensation for the many known unknowns.  
Although these guidelines have helped establish a new higher standard for chemical probes used 
within research, the transition of replacing the previously used under characterised chemical probes 
with new higher quality probes, is largely thanks to a collection of public-private consortiums such as 
the Structural Genomics Consortium (SGC)[4] and chemicalprobes.org[5]. Partnerships such as these 
have sought to raise awareness of the  ?promise and perils ? of chemical probes, whilst providing access 
to all the information available on existing probes, even offering guidance on the optimal probe for a 
particular target and appropriate concentrations for its use. 
The combination of higher quality probes and an improved awareness has already led to a number of 
breakthroughs in scientific research, arguably none bigger than for the BET bromodomain family, 
which will now be used as a case study to demonstrate the power of small molecule chemical probes 
and their evolving use in target validation.  
In 2010 two separate groups identified (+)-JQ-1 and I-BET762 as potent and highly selective inhibitors 
of the BET bromodomains. Whilst being high quality, well characterized chemical probes, they were 
both also accompanied by a negative control in the form of their inactive enantiomer, allowing for 
phenotypic screening studies[6]. Instead of keeping this information to themselves, the structures and 
properties of both molecules were made available for the scientific community. Several other groups 
followed suit with other BET probes, such as I-BET151, PFI-1 and OXF BD 02, which together created 
a diverse portfolio of chemotypes, suitable to thoroughly investigate the BET bromodomains target 
validity. In doing so, the biological function of this family of bromodomains, and the role they play in 
a number of diseases, was vigorously interrogated, ultimately accelerating bromodomain drug 
discovery[7]. As of 2017 there are currently 16 BET bromodomain clinical candidates spanning 14 
different companies, underpinning the value of (+)-JQ-1 and I-BET762 as extremely successful and 
effective chemical probes[1,8,9]. 
Whilst (+)-JQ-1 and I-BET762 are classical examples of high quality chemical probes, there are multiple 
alternative approaches utilising small molecule probes for target validation. For example, the 
aforementioned BET chemical probes, whilst being highly pan-selective for BET bromodomains over 
other bromodomains, all display poor selectivity within the BET subfamily, preventing the direct 
assignment of BET inhibitor pharmacology to a particular bromodomain target. The  ?ďƵŵƉ-and-hole 
ĂƉƉƌŽĂĐŚ ?, previously used in selective kinase inhibition, has attempted to address this issue, utilising 
the existing probe I-BET762. Mutation of a conserved leucine residue [L94 in Brd4(1)] to a sterically 
smaller alanine, and the introduction of an ethyl group to an I-BET762 derivative, produced the 
ĂĨŽƌĞŵĞŶƚŝŽŶĞĚ ?ŚŽůĞ ?ĂŶĚ ?ďƵŵƉ ?ƌĞƐƉĞĐƚŝǀĞůǇ ?ĨƌŽŵǁŚŝĐŚBET subfamily selectivity was achieved. 
Displaying up to 540 fold selectivity for mutated bromodomains over regular, this ethyl derivative of 
I-BET762 was used to dissect the individuĂůƌŽůĞŽĨƌĚ ? ?ƐďƌŽŵŽĚŽŵĂŝŶƐŝŶĐŚƌŽŵĂƚŝŶďŝŶĚŝŶŐ, thus 
demonstrating the potential for the bump-and-hole technique in the generation of new selective 
chemical probes, and their value in the interrogation of drug targets[10].  
Utilising the structural information typically obtained during the development of chemical probes 
facilitates the development of bifunctional chemical biology tools.  One such important research area 
at the interface of drug discovery, chemical biology and target validation is proteolysis targeting 
chimeras (PROTACs). Fundamentally, PROTACs work by combining two protein binding regions, one 
region which binds to the target protein and another which binds to E3 ligase. Together they create a 
bifunctional molecule capable of facilitating ubiquitination of the target protein and thus ultimately 
proteolysis. A recent example of this is for the treatment of castration resistant prostate cancer (CRPC) 
where (+)-JQ-1 was utilised to exploit its high selectivity and potency for BET bromodomains [11]. The 
result of which was ARV-771, a highly potent (IC50 <5 nm) BET PROTAC which has been shown to 
selectively degrade BET proteins and induce CRPC cell apoptosis in vitro. Furthermore, ARV-771 has 
also been shown to reduce the levels of two key androgen receptors (full length androgen receptor 
and androgen receptor variant 7) present in prostate cancer cells, both of which are strongly linked to 
CRPC[12]. (+)-JQ-1 based PROTACs have also been used to selectively degrade BRD4, again providing 
more information on selective BET subfamily suppression[13]. 
Also taking advantage of structural information around (+)-JQ-1, biotin was attached via a 
polyethylene glycol (PEG) linker to create bio-JQ1, a bifunctional small molecule capable of facile 
ligand-affinity capture. Used alongside Chem-seq, a parallel DNA sequencing technique, it was 
possible to map the direct interactions between small molecules and bromodomain containing 
proteins BRD2, BRD3 and BRD4 within the genome, providing further insight into the mechanisms by 
which BET inhibitors perturb gene expression[14]. 
Finally, photoaffinity labelling probes are an important chemoproteomic tool due to their ability to 
covalently label their biological targets. Seeking to replace the acetyl lysine mimetic of the CREBBP 
probe SGC-CBP30, Jones and co-workers identified a novel photoreactive tropolone warhead, and 
hypothesized that photoaffinity labels could be developed for bromodomains. Shown to indeed be 
possible, a clickable derivative was accessed which was used to understand the direct biological 
targets of the probe and assess BRD4 target engagement by (+)-JQ-1 [15,16]. Clickable photoaffinity 
labelling probes have also been used to map thousands of site specific small molecule-protein 
interactions within human cells, from which more potent and selective small molecules can be 
optimised, presenting this technique as a versatile approach to small molecule discovery as we 
advance into the future[17].  
As demonstrated with bromodomain probes, the area of chemical probes is continuously evolving, 
with more valuable and sophisticated approaches to small molecule enabled target validation being 
developed constantly. This is encapsulated by recent work investigating the epigenetic reader YEATS 
domain containing protein ENL, in the treatment of acute myeloid leukaemia. Using CRISPR-Cas9 gene 
editing and a targeted PROTAC approach, ENL was identified as an oncogenic transcription regulator 
involved in acute myeloid leukaemia. ENL displacement from chromatin was shown, with in vitro and 
in vivo evidence, to reduce oncogenic gene expression whilst simultaneously sensitizing leukaemia 
cells to BET inhibitors, presenting a promising stand alone epigenetic therapy for acute myeloid 
leukaemia, or as a combination therapy with BET inhibitors[18,19]. When considering the role of small 
molecules in target validation, it is of note that CRISPR often uses small molecule enhancers, such as 
RS-1 and L755507, to improve efficiency and precision via various mechanisms[20]. 
In conclusion, high quality chemical probes and their derivatives are invaluable to the pre-clinical 
target validation tool set, acting as powerful research tools, resource savers, and a potential source 
for new medicines. This coupled with a greater understanding and appreciation of high quality 
chemical tools will hopefully lead to an increase in successful target validation in the future, and a 
reduction in clinical attrition. 
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